Cannassure Therapeutics Ltd (TA:CSURE) — Stock Price
Cannassure Therapeutics Ltd (TA:CSURE) is currently trading at ILA600.00 ILA, up 2.34% today. Over the past 52 weeks, shares have ranged between ILA585.20 and ILA840.00. This page tracks Cannassure Therapeutics Ltd's live share price on the TA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CSURE market cap overview.
Cannassure Therapeutics Ltd (CSURE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Cannassure Therapeutics Ltd's daily closing share price and trading volume on the TA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Cannassure Therapeutics Ltd Income Statement — Revenue, Profit & Earnings by Year
Cannassure Therapeutics Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year |
|---|
| Total Revenue |
| Cost of Revenue |
| Gross Profit |
| Research & Development |
| SG&A |
| Total Operating Expenses |
| Operating Income |
| EBITDA |
| EBIT |
| Interest Expense |
| Income Before Tax |
| Income Tax Expense |
| Net Income |
Cannassure Therapeutics Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Cannassure Therapeutics Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year |
|---|
| Total Assets |
| Total Current Assets |
| Cash & Equivalents |
| Short-term Investments |
| Net Receivables |
| Inventory |
| Property, Plant & Equipment |
| Goodwill |
| Total Liabilities |
| Total Current Liabilities |
| Long-term Debt |
| Net Debt |
| Total Stockholder Equity |
| Retained Earnings |
Cannassure Therapeutics Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Cannassure Therapeutics Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|
| Operating Cash Flow | ILA-20.82 Million | ILA-12.16 Million | ILA-3.50 Million | ILA-3.50 Million |
| Capital Expenditures | ILA4.20 Million | ILA12.50 Million | ILA4.78 Million | ILA4.78 Million |
| Free Cash Flow | — | — | — | — |
| Investing Cash Flow | ILA-4.20 Million | ILA-9.79 Million | ILA-3.64 Million | ILA-3.64 Million |
| Financing Cash Flow | ILA15.64 Million | ILA13.62 Million | ILA25.49 Million | ILA25.49 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | — | — | — | — |
| Depreciation | ILA5.72 Million | ILA2.60 Million | ILA13.00K | ILA13.00K |
| Change in Cash | ILA-9.38 Million | ILA-8.32 Million | ILA18.35 Million | ILA18.35 Million |
Cannassure Therapeutics Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Cannassure Therapeutics Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for Cannassure Therapeutics Ltd.